Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
Rhea-AI Summary
Compugen (Nasdaq:CGEN), a clinical-stage cancer immunotherapy company using AI/ML for computational target discovery, will participate in Jones Trading's “Mapping the Path from Target to Patient” Fireside Chat Series with leaders in AI/ML-based drug development.
The event is scheduled for Monday, June 15, 2026, from 10:30–11:00 AM ET, with a live webcast and replay available via Compugen's investor relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CGEN
In the Jun 8 session, CGEN declined 2.86%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Fireside chat date
- June 15, 2026
- Jones Trading AI/ML-based drug development fireside chat
- Event time
- 10:30–11:00 AM ET
- Scheduled duration of Compugen management fireside chat
- Price move
- -5.41%
- Change prior to AI/ML fireside chat announcement
- 52-week range position
- -35.39% vs high / 61.39% vs low
- Price <b>$2.09</b> relative to 52-week range
Previous AI Reports
-
Enhanced Unigen AI/ML platform via single cell sequencing collaboration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLON,
A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations. Currently, Compugen is conducting a blinded randomized ovarian cancer platform trial evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 program, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen's has an early-stage immuno-oncology pipeline consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Company contact:
Lindsey Trickett
Email: LindseyT@cgen.com
Tel: +1 415 373 0892
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-jones-trading-fireside-chat-series-with-leaders-in-aiml-based-drug-development-302793851.html
SOURCE Compugen Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.